Mode
Text Size
Log in / Sign up
N/A N=31 Treatment

An Evaluation of the Effect of the Erchonia Laser for Non-invasive Reduction of Submental Fat

Weight Loss

Enrolled (actual)
31
Serious AEs
0.0%
Results posted
Aug 2025
Primary outcome: Primary: Proportion of Accurately Identified Subject Pre- and Post-treatment Photographs by at Least Two of the Three Blinded Independent Evaluators. — 26 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Erchonia CFL Laser (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Erchonia Corporation
Primary completion
May 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Proportion of Accurately Identified Subject Pre- and Post-treatment Photographs by at Least Two of the Three Blinded Independent Evaluators.
26
SECONDARY
Change in Submental Skinfold Thickness (mm)
-2.71

Summary

The purpose of this clinical study is to determine the effectiveness of the Erchonia® CFL (manufactured by Erchonia Corporation (the Company), in providing noninvasive fat reduction in the submental area.

Eligibility Criteria

Inclusion Criteria

  • Male or female 18 to 65 years of age, inclusive.
  • Submental and submandibular skin fold thickness > 1cm (measured by caliper).
  • Subject agrees to maintain his/her weight (i.e., within 5%) by not making any major changes in diet or exercise routine during the course of the study.
  • Subject agrees to abstain from partaking in any treatment to promote body contouring and/or weight loss during the course of study participation. Such treatments include, but are not limited to:
  • over-the-counter and/or prescription medications; dietary/herbal supplements and appetite suppressants.
  • weight loss programs/diet plans.
  • surgical procedures for sculpting of the chin fat pad/weight loss, e.g. submental lipectomy, lap bands.
  • Subject has signed a written informed consent form.

Exclusion Criteria

  • Evidence of any cause of enlargement in the submental area other than localized subcutaneous fat, such as swollen lymph nodes or ptotic submandibular glands.
  • Treatment with dermal fillers, radiofrequency or laser procedures, or chemical peels in the neck or chin area (below the mandible) within the past 6 months.
  • Botulinum toxin or other aesthetic drug injections within the neck or chin area (below the mandible) within the past 6 months.
  • History of a fat reduction procedure (e.g., liposuction, surgery, lipolytic agents, etc.) or implant in or adjacent to the area of intended treatment.
  • Any dermatological conditions, such as scars in the location of the treatment area that may interfere with the treatment or evaluation.
  • Active implanted device such as a pacemaker, defibrillator, or drug delivery system.
  • Pregnant or intending to become pregnant in the next 6 months.
  • Currently enrolled in a clinical study of an unapproved investigational drug or device.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05954065). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search